Brief: Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
06/06/2024 13:11
June 6 (Reuters) - Harrow Inc HROW.O :
* MELT PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
PIVOTAL
PHASE 3 PROGRAM OF ITS LEAD PRODUCT CANDIDATE, MELT-300, FOR
NEEDLE- AND OPIOID-FREE SEDATION IN PATIENTS UNDERGOING CATARACT
SURGERY
* HARROW INC: TOPLINE READOUT EXPECTED IN Q4 2024
Source text for Eikon: ID:nBw3Tbcxla
Further company coverage: HROW.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates